enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Erenumab - Wikipedia

   en.wikipedia.org/wiki/Erenumab

   Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. [ 3 ] [ 4 ] [ 5 ] It is administered by subcutaneous injection .

3. FDA approves first drug to prevent migraines - AOL

   www.aol.com/news/2018-05-18-fda-approves-first...

   The Food and Drug Administration approved on Thursday the first drug designed to prevent migraines. A once-monthly, self-injection, Aimovig is the first in a new class of long-acting drugs that is ...

4. Prostvac - Wikipedia

   en.wikipedia.org/wiki/Prostvac

   PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]

5. Androgen deprivation therapy - Wikipedia

   en.wikipedia.org/wiki/Androgen_deprivation_therapy

   Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

6. 5α-Reductase inhibitor - Wikipedia

   en.wikipedia.org/wiki/5α-reductase_inhibitor

   [9] [10] It can also reduce DHT levels in the prostate by 97 to 99% in men with prostate cancer. [11] [12] Epristeride (brand names Aipuliete, Chuanliu) is marketed in China for the treatment of benign prostatic hyperplasia. [13] [14] [15] However, it can only decrease circulating DHT levels by about 25 to 54%. [16]

7. Comparison of bicalutamide with other antiandrogens

   en.wikipedia.org/wiki/Comparison_of_bicalutamide...

   A 2015 Cochrane review found that NSAA monotherapy for prostate cancer had a greater risk of treatment discontinuation due to adverse effects than monotherapy with a GnRH agonist or surgical castration (RR = 1.82). [122] This included a greatly increased risk of breast pain (RR = 22.97) and gynecomastia (RR = 8.43). [122]